Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis

JAMA Neurology

Volumn 71, Issue 9, 2014, Pages 1192-

  Warnke, Clemens ^a   Adams, Ortwin ^b   Kieseier, Bernd ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Orthopedic Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; INTERFERON; NATALIZUMAB; VIRUS DNA; CD19 ANTIGEN; CD34 ANTIGEN; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; BLOOD VOLUME; BONE MARROW CELL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DNA DETERMINATION; DNA METABOLISM; EXTRAVASATION; GENE DOSAGE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LETTER; LYMPHOCYTE MIGRATION; LYMPHOCYTOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; T LYMPHOCYTE SUBPOPULATION; URINE; VIRUS CARRIER; ANIMAL; BLOOD; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTIGENS, CD34; HUMANS; JC VIRUS; MULTIPLE SCLEROSIS;

EID: 84907512225     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1855     Document Type: Letter

References (5)

1. Frohman EM, Monaco MC, Remington G, et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 2014;71(5):596-602.
2. Warnke C, Smolianov V, Dehmel T, et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler. 2011;17(2):151-156.
3. Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011;68(11):1428-1431.
4. Chalkias S, Dang X, Bord E, et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol. 2014;75(6):925-934.
5. Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 2013;81(16):1400-1408.